You are here

Article Scans

Comment

Discuss

Brief reviews of recently published articles, organized by stem cell type.

December 13, 2011 | Pluripotent Stem Cells

From Stem Cells
By Stuart P. Atkinson

Induced pluripotent stem cell (iPSC) technology not only has the capability to produce patient-specific but also disease-specific pluripotent cells. In monogenic diseases, there lies the potential for gene modification allowing differentiation of therapeutically relevant “corrected” cells, as has been demonstrated in mouse iPSCs...

December 13, 2011 | Pluripotent Stem Cells

From Cell
By Stuart P. Atkinson

Although multiple studies over the last 5-10 years have begun to unravel the complex network which underlies the pluripotent state of embryonic stem cells (ESCs), bringing together transcription factors, small RNA species, chromatin and DNA methylation events, the specific molecular determinants of the pluripotent state are yet to be fully...

November 18, 2011 | Direct Reprogramming

From PNAS
By Carla Mellough

It is just 5 years since Takahashi and Yamanaka demonstrated that both embryonic and adult mouse somatic cells could be reprogrammed back to a pluripotent state, creating induced pluripotent stem cells (iPSCs). In the short time since this achievement the equivalent has been demonstrated across multiple human somatic cell types, which has...

November 10, 2011 | Pluripotent Stem Cells

From the October Edition of Stem Cells
By Stuart P. Atkinson

A brief report in the October edition of Stem Cells from the laboratory of Steven L. Stice at the University of Georgia, Athens, Georgia, USA describes the ability of pig induced pluripotent stem cells (piPSCs) to be transmitted through the germline and studies the effect of piPSC incorporation on offspring...

November 10, 2011 | Epiblast Stem Cells

From the October Edition of Stem Cells
By Stuart P. Atkinson

Epiblast stem cells (EpiSCs) are derived from postimplantation mouse embryos from embryonic day (E) 5.5 to E7.5 (Brons et al and Tesar et al) and appear to share more characteristics with human embryonic stem cells (hESCs) than with mouse ESCs (mESCs) (Greber et al). EpiSCs are...

November 10, 2011 | Pluripotent Stem Cells

From Nature
By Stuart P. Atkinson

When induced pluripotent stem cell (iPSC) technology broke onto the scene in 2007, the attainment of a practical and ethical source of patient specific pluripotent stem cells seemed to be within our grasp. The use of somatic cell nuclear transfer (SCNT) for the derivation of human embryonic stem cells (hESCs) was all but relegated to the...

November 10, 2011 | Mammary Stem Cells

From the October Edition of Stem Cells
By Stuart P. Atkinson

The E-twenty six transcription factor, Elf5, has been previously identified as an important regulator of mammary alveolar development (Oakes et al and Choi et al). Elf5 is not expressed in the stem cell-enriched compartment of the mammary gland, but is expressed in both luminal progenitors and...

October 21, 2011 | Haematopoetic Stem Cells

From Blood
By Stuart P. Atkinson

The chronic lack of donated blood, with an annual requirement of nearly 90 million units worldwide presents a major problem which, with an increasing world population, will only get worse. Apart from typical blood donation, another possible source of blood cells is through in vitro manipulations of stem cell populations, such as...

October 14, 2011 | Haematopoetic Stem Cells

From the July Edition of Stem Cells
By Stuart P. Atkinson

The study of embryonic development of the hematopoietic system has allowed us to uncover many of the key molecular mechanisms that act at the various different stages. Taking such information into consideration, Woods et al from the lab of Inder M. Verma at the Salk Institute for Biological Studies, La Jolla,...

October 14, 2011 | Pluripotent Stem Cells

From the July Edition of Stem Cells
By Stuart P. Atkinson

The risk of immune rejection and tumorigenesis of cells derived from pluripotent stem cells are both major concerns for regenerative medicine. The generation of patient specific induced pluripotent stem cells (iPSCs) promises a way round the problem of immunotolerance in cell/tissue replacement therapy, but iPSC...

Pages